{"filing":{"accession_number":"0001398733-26-000052","cik":"0001398733","ticker":"AQST","company_name":"Aquestive Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"aqst-20260929.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1398733/000139873326000052/aqst-20260929.htm"},"events":[{"id":35586,"run_id":32785,"accession_number":"0001398733-26-000052","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the Board's election of Richard J. Daly as a director effective October 14, 2026. The principal action is a person taking a role—Daly's appointment to the Board as a Class I director. While the disclosure also mentions compensatory arrangements (57,000 stock options), the core event is the appointment itself. This is material because board composition changes affect governance and investor assessment of the company's leadership and strategic direction.","company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39686,"accession_number":"0001398733-26-000052","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the Board's election of Richard J. Daly as a director effective October 14, 2026. The principal action is a person taking a role—Daly's appointment to the Board as a Class I director. While the disclosure also mentions compensatory arrangements (57,000 stock options), the core event is the appointment itself. This is material because board composition changes affect governance and investor assessment of the company's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:23:37.803345+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39686,"accession_number":"0001398733-26-000052","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the Board's election of Richard J. Daly as a director effective October 14, 2026. The principal action is a person taking a role—Daly's appointment to the Board as a Class I director. While the disclosure also mentions compensatory arrangements (57,000 stock options), the core event is the appointment itself. This is material because board composition changes affect governance and investor assessment of the company's leadership and strategic direction.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:23:37.803345+00:00","company_name":"Aquestive Therapeutics, Inc.","ticker":"AQST","filing_date":"2026-09-29"}]}